Consolidated Portfolio Review Corp Bristol Myers Squibb CO Transaction History
Consolidated Portfolio Review Corp
- $632 Billion
- Q4 2024
A detailed history of Consolidated Portfolio Review Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Consolidated Portfolio Review Corp holds 42,066 shares of BMY stock, worth $2.39 Million. This represents 0.38% of its overall portfolio holdings.
Number of Shares
42,066Holding current value
$2.39 Million% of portfolio
0.38%Shares
2 transactions
Others Institutions Holding BMY
# of Institutions
2,639Shares Held
1.46BCall Options Held
31.5MPut Options Held
34.9M-
Vanguard Group Inc Valley Forge, PA189MShares$10.7 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY159MShares$9.02 Billion0.15% of portfolio
-
State Street Corp Boston, MA92.9MShares$5.28 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY77.9MShares$4.43 Billion0.33% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA60.3MShares$3.43 Billion0.65% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $121B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...